Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 9:30 PM
Ignite Modification Date:
2025-12-24 @ 9:30 PM
NCT ID:
NCT06108232
Brief Summary:
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
Detailed Description:
Objectives:
Primary Objectives:
• To determine the efficacy of obinutuzumab in combination with CC-99282 as determined by complete response (CR) rate after six cycles of combination treatment for patients with previously untreated, high tumor burden follicular lymphoma (FL).
Secondary Objectives:
• To determine best overall response rate (ORR), duration of response (DOR), time to next treatment, CR rate at 30 months (CR30), progression-free survival (PFS), overall survival (OS), and evaluation of safety of obinutuzumab and CC-99282 as treatment for previously untreated patients with FL.
Exploratory Objective:
* To determine the biomarkers that correlates with response and mechanisms of resistance to obinutuzumab and CC-99282 in FL.
* To determine the quality of life in patients with FL receiving obinutuzumab and CC-99282
Study:
NCT06108232
Study Brief:
Protocol Section:
NCT06108232